Treatment of Sh3tc2−/− mice at the age of 3 weeks resulted in significant improvement of several pathological features indicating that this approach could be further developed to treat CMT4C patients. The gene discussed is SH3TC2; the disease is Charcot-Marie-Tooth disease type 4C.